2020-05-06 10:25
Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14:00 to 16:00. Biovica is nearing market launch of DiviTum® in the US for the monitoring of metastatic breast cancer treatments. DiviTum® is...
2020-04-29 11:38
Biovica is nearing market launch of DiviTum® in the US for the monitoring of metastatic breast cancer treatments. DiviTum® is already being sold for research purposes, primarily to major pharmaceutical companies for use in clinical studies. After...
2020-04-08 08:00
The main purpose of including DiviTum® in studies performed at Mayo Clinic is to evaluate the changes in serum thymidine kinase activity, measured by DiviTum®, in patients with hormone positive metastatic breast cancer treated with today’s...
2020-03-25 08:30
“As DiviTum® is approaching commercialization we are strengthening the team. Robert brings insights from cancer diagnostics as well as therapeutics and has an excellent track record of successful product launches which will be valuable when...
2020-03-12 08:30
The study evaluated thymidine kinase activity in 142 women with newly diagnosed metastatic breast cancer as a tool for first-line prognosis and monitoring. Activity was measured by Biovica's DiviTum test at diagnosis and after 1, 3 and 6 months of...
2020-03-12 08:00
Significant events during the third quarter Significant events after the end of the period Audiocast When: 12 March 2020 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q3-2019-2020 or SE: +46850558352 / DK: +4578150110...
2020-03-10 22:03
“We are pleased with our results in the analytical validation, which is part of our FDA application and so far meet the criteria we have set. However, a component supplier has had delivery delays which means that we now anticipate being able to...
2020-01-16 08:00
“We are very pleased that these results, which were initially presented at the AACR annual meeting 2019, are published in the renowned journal Clinical Cancer Research. The data shows that DiviTum® can be used to evaluate the treatment efficacy...
2019-12-06 08:00
“Henrik possesses a rare combination of scientific expertise and commercial experience. With his many years of diagnostics background, he brings with him tremendous insight and an extensive network of contacts. Henrik is an important piece of the...
2019-12-05 08:00
Period: May-October 2019/2020 Significant events during the second quarter Significant events after the end of the period Audiocast When: 6 December 2019 at 10.00 CET
Where: https://tv.streamfabriken.com/biovica-international-q2-2019...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects